Horizon Therapeutics has become the first company to receive the regulatory approval of its drug Tepezza for the cure of Thyroid Eye
Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye is a progressive autoimmune disorder hampering the ability of vision. The drug was approved under Priority Review and had received Orphan Drug, Fast Track and Breakthrough Therapy designations from the FDA.
Thyroid eye is a rare disease; however, up to 50 per cent of patients with Graves’ disease, the most common autoimmune disorder, are at the risk of developing TED.
Tepezza is a fully human monoclonal antibody (mAb) and a targeted inhibitor ...
